Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap
This article was originally published in The Pink Sheet Daily
Executive Summary
With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.